FIELD: pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition for inhalation. Above composition contains as the only active ingredient aclidinium in form of dry powder mixed with pharmaceutically acceptable carrier in form of dry powder, where weight ratio of aclidinium and carrier makes from 1:25 to 1:75, and metered nominal dose of aclidinium is equivalent to 400 mcg (plus / minus 10 %) of aclidinium bromide. Invention also relates to methods of treating respiratory disorder specified from asthma and chronic obstructive pulmonary disease, which involve administering said composition and multi-dose inhalation device calibrated to facilitate introduction of measured nominal dose of aclidinium, equivalent to 400 mcg (plus / minus 10 %) of aclidinium bromide.
EFFECT: invention provides considerable and stable increase in forced expiratory volume per second in patients with COPD.
14 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATIONS | 2011 |
|
RU2585101C2 |
| NOVEL APPLICATION OF BUDESONIDE AND FORMOTEROL | 1998 |
|
RU2199322C2 |
| AEROSOL COMPOSITION CONTAINIG PHOMOTHEROL | 2000 |
|
RU2327452C2 |
| COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2484823C2 |
| PHARMACEUTICAL DRUG FORMS CONTAINING LOW-DOSAGE ACTIVE COMPONENT FOR DRY POWDER INHALATORS | 2005 |
|
RU2371171C2 |
| COMBINATIONS CONTAINING ANTI-MUSCARINE PREPARATIONS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2379033C2 |
| NOVEL CARRIER PARTICLES FOR DRY POWDER INHALATION FORMULATIONS | 2020 |
|
RU2823554C1 |
| PRE-DOSED DRY POWDER INHALER FOR MOISTURE-SENSITIVE MEDICINES | 2004 |
|
RU2372946C2 |
| INHALATION COMPOSITIONS CONTAINING MONTELEUKAST ACID AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | 2008 |
|
RU2470639C2 |
| COMBINATIONS CONTAINING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | 2005 |
|
RU2404771C2 |
